Tapping Psychedelics for their Anti-Inflammatory Powers

The Bio Report


Joining us daniel pleasure. We're going to talk about the therapeutic. Potential of psychedelics loose and it's pipelines experimental therapies that extend well beyond mental health indications. There's a growing interest in psychedelics. as medicines what's led to the transformation of this area from one of illicit substances to wonder drugs. Well i think that science has led the way And really it's been clinical research conducted at the top universities around the world Principally johns hopkins to start and now all over imperial college yale university new york university etc Very much led by the science. I i think that When you the question of wonder drugs though is interesting because i think that Silla sabin like ketamine are drugs that have a tremendous amount of promise for the treatment of depression within psychiatry and these drugs have therapeutic potential and other drugs beyond psychiatry but The classification wonder always brings the kind of and probably justifiable skepticism of Is the hype real. And what's really kind of the fundamental Potential and also what are the stumbling blocks for these therapies. And so all of those things are really the focus of the company in in in looking to develop These therapies both within and beyond psychiatry. How restrictive an area is this to work in today. And historically how hampered his research been it has never been more easy to do research in this area You know over the last forty fifty years. Things have dramatically changed. I think that What's what's really notable is the amount of knowledge that the regulators have in this space. The fda ema are very well informed about both the therapeutic potential of these drugs as well as the the risks associated with their development and use. And so i think you have a very informed regulatory audience and you also have increasingly Investors and other sources of capital that are willing to explore and develop these therapies. So i don't see really the limitation being that of a regulatory or legal wine and it's much more about The you know the the aspects of clinical development and really how do you take something with potential and translate that into a solution to address. Unmet needs there's long been interest in the potential of these substances to treat depression and addiction. But you're looking at a broader range of diseases. Among other things you're looking at these substances potential anti inflammatories. What's understood about the potential use of these drugs as anti inflammatories. I think that you know. Our company is is really notable for the fact that we have the the world's leading scientists and clinical developers focused on the full range of potential. Both within and beyond psychiatry. Interestingly when people think about serotonin they think about it in the context of depression they think about it in the context of psychiatry but actually serotonin is a modulator of basic function throughout the body And in fact there's more serotonin in our in our gut than in our brain and in particular the primary target of psychedelics. The new the The primary receptor which mediates the psychedelic effects of serotonin. Two a receptor is ubiquitously expressed throughout the body. It's on all immune cells. It's on all major organ systems and so fundamentally We have been away dazzled and and a bit distracted by the profound psychiatric potential of these drugs and certainly their perceptual effects. But in reality there is a much broader potential because these appear to modulate Stress response in a variety of ways. You know you if you think of it in the context of psychiatry than depression or anxiety or substance abuse are all in a way related to the kind of inappropriate or maladaptive response to stress in the rest of the body. You know whether it's Due to aging whether it's due to an inappropriate immune response we see. Similar type of modulating where the serotonin receptor seems to be implicated in a variety of chronic. Inflammatory diseases the initial discovery of the potent anti inflammatory effects of some psychedelic. Compounds was was. I made by our scientific founder. Professor charles nichols at lsu. The that research That kind of kicked off a long Research campaign in the development of anti of the anti inflammatory potential psychedelics has less through A number of very interesting discovery specifically that some psychedelics are potently anti inflammatory in models of allergic asthma in cardiovascular disease and in a variety of different models of of inflammatory disease associated with ophthalmology related to diabetic. Retinopathy macular degeneration in addition to which there is potential in neuro degeneration and a variety of other conditions and so fundamentally the potential is massive and the key. Question is and really. I think we've addressed this and we're we're very excited to kind of take the next is. How do you bias the psychedelic from its perceptual effects. And make it purely a anti-inflammatory or immunomodulators medicine and that's something that we are

Coming up next